Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study.

Autor: Desai SH; Division of Hematology, Mayo Clinic, Rochester, MN, USA., LaPlant B; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Macon WR; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., King RL; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Wang Y; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Inwards DJ; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Micallef I; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Johnston PB; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Porrata LF; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Ansell SM; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Habermann TM; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Witzig TE; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, MN, USA. Nowakowski.Grzegorz@mayo.edu.
Jazyk: angličtina
Zdroj: Blood cancer journal [Blood Cancer J] 2021 Sep 25; Vol. 11 (9), pp. 160. Date of Electronic Publication: 2021 Sep 25.
DOI: 10.1038/s41408-021-00542-z
Abstrakt: Diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from follicular lymphoma (FL) is often excluded from clinical trials. Lenalidomide has response rates of 45% in relapsed transformed DLBCL. Herein we present an analysis of MC078E, a phase II clinical trial testing lenalidomide plus R-CHOP (R2CHOP) for patients with untreated transformed/concurrent DLBCL (NCT00670358). Adult patients with transformed or concurrent DLBCL were included. Patients received six cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) with lenalidomide 25 mg days 1-10 of each cycle. The primary outcome was progression-free survival (PFS) at 24 months. Secondary outcomes were response rates, event-free survival (EFS), and overall survival (OS). Thirty-nine patients were accrued from August 5, 2013 to July 28, 2020 and 33 were eligible by central pathology review. The median age was 64 (24-80) years, 18 (54%) were male, 25 (76%) were concurrent and 8 (24%) were transformed DLBCL. The PFS, EFS, and OS rates at 24 months were 84.4% (CI 95 : 67.2-94.7%), 84.5% (CI 95 : 72.9-98%), and 97.0% (CI 95 : 91.3-100%), respectively. R2CHOP is effective in concurrent and transformed DLBCL. The study supports the inclusion of anthracycline-naive transformed and concurrent DLBCL in future clinical trials of novel immunomodulatory analogues.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: